Non-small-cell lung cancer (NSCLC) (ROS1 +)

No distinction is made here between ROS1 fusions and ROS1 mutations, although they are two distinct genetic alterations.

The ROS1 gene rearrangement is estimated to occur in 2–4.69% of all patients with NSCLC, with an incidence of approximately 4000 cases in the USA, annually
Rikova et al. 2007 Cell 131(6): 1190-1203
Bergethon et al. 2012 J. Clin. Oncol. 30(8): 863-870
AACR Project GENIE Consortium 2017 Cancer Discov. 7(8): 818-831
Tremblay et al. 2022 Future Oncol. 18(17): 2063-2074

Recurrent gene fusions, such as ROS1 fusions, are oncogenic drivers of various cancers, including non-small-cell lung cancer (NSCLC). Up to 36% of patients with ROS1 fusionpositive NSCLC have brain metastases at the diagnosis of advanced disease.
Drilon et al. 2020
…